Ari Baron, M.D. , Scientist; Medical Director of the Clinical Oncology Research Program at CPMC, Chief of Medical Oncology/Hematology

California Pacific CURRENTS: The online journal of CPMC Research Institute

Clinical trials for pancreatic, prostate, colon, liver, lung, breast, and ovarian cancers at CPMC
  • weekly patupilone in patients with prostate cancer

    Kaplan–Meier estimates of the time to progression are shown above. The median time to progression was 1.6 months [95% confidence interval (CI) = 1.4, 1.9 months]. The median OS for chemotherapy-naive and chemotherapy-treated patients was essentially identical; for the entire enrolled population, it was 13.4 months (95% CI = 10.7, 16.5 months).

    Source: Hussain A, DiPaola RS, Baron AD, Higano CS, Tchekmedyian NS, Johri AR. Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol 2009;20(3):492-7. doi: 10.1093/annonc/mdn665. Epub 2008 Dec 15. (Adapted from Figure 1)

  • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

    The median duration of survival (indicated by the dotted lines) was 20.3 months in the group given irinotecan, fluorouracil, and leucovorin (IFL) plus bevacizumab, as compared with 15.6 months in the group given IFL plus placebo, corresponding to a hazard ratio for death of 0.66 (p<0.001).

    Source: Hurwitz H, Fehrenbacher L, … Baron A, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42. (Adapted from Figure 1)


Research Overview

  • Dr. Baron leads an innovative oncology drug and chemotherapy trials programs for solid tumors at CPMC. He is Chair of the Science Committee for the Sutter Cancer Research Consortium.
  • His outcomes research is incorporated into the program to ensure patients receive the most effective therapies.
  • For pancreatic tumors, Dr. Baron’s clinical trials program is closely linked with interventional endoscopy specialists and surgeons to improve the diagnosis and treatment of cancer.
  • Dr. Baron and colleagues at CPMC are conducting clinical trials to determine the efficacy of vaccine immunotherapy in shrinking tumors prior to surgery, and to investigate recombinant smallpox vaccine in liver cancer patients for whom surgery and traditional chemotherapies have been ineffective.
  • He is the Science Chair for the Sutter Cancer Research Consortium.

Listen to Dr. Baron's perspectives on new advances in cancer research at Sutter Health.


Dr. Baron obtained his M.D. from Tufts University School of Medicine in Boston, Massachusetts, and completed residency training and a hematology-oncology fellowship at the University of California, San Francisco.

Publication Search


Thomas MB, Garrett-Mayer E, Anis M, Anderton K, Bentz T, Edwards A, Brisendine A, Weiss G, Siegel AB, Bendell J, Baron A, Duddalwar V, El-Khoueiry A, A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma. Oncology

Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL, Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet

Patt YZ, Murad W, Fekrazad MH, Baron AD, Bansal P, Boumber Y, Steinberg K, Lee SJ, Bedrick E, Du R, Lee FC, INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial. Cancer Med

Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX, Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. Eur J Cancer

Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JÁ, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD, Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol

Zhu AX, Baron AD, Malfertheiner P, Kudo M, Kawazoe S, Pezet D, Weissinger F, Brandi G, Barone CA, Okusaka T, Wada Y, Park JO, Ryoo BY, Cho JY, Chung HC, Li CP, Yen CJ, Lee KD, Chang SC, Yang L, Abada PB, Chau I, Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score. JAMA Oncol

Ari Baron, M.D. , Scientist; Medical Director of the Clinical Oncology Research Program at CPMC, Chief of Medical Oncology/Hematology
Primary Research Interests
  • Treatment of solid tumors
  • Vaccine immunotherapies for can

Cancer Clinical Trials

Research News & Highlights

In Sept. 2016, Dr. Baron and colleauges published updated results of the REACH study assessing the efficacy and safety of the monoclonal antibody ramucirumab for the treatment of advanced liver cancer. Learn more about the study.